ERNA Ernexa Therapeutics Inc.
USHealthcareAs of 2026-07-09 16:00
Why ERNA matters now
Ernexa Therapeutics Inc. (ERNA) is a US stock in Healthcare. The latest InvestLog snapshot shows $5.93 with +3.49% on the session and $1.9M in market capitalization; recent performance reads 1-month -45.85% and YTD -79.33%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-5.5M, and EPS of $-6.95. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -372.5%.
The latest indexable market news headline is "Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Cherington Charles filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.72
P/S
0.00
EV/EBITDA
0.41
DCF Value
$1.93
FCF Yield
-372.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-263.7%
ROA
-108.0%
ROIC
-138.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-5.5M | $-6.95 |
| Q4 2025 | $0.00 | $-1.5M | $-4.75 |
| FY 2025 | $0.00 | $-14.1M | $-56.00 |
| Q3 2025 | $0.00 | $-1.2M | $-3.75 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.50
Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer. Additionally, Ernexa is developing ERNA-102, an iMSC product engineered to secrete the anti-inflammatory cytokine IL-10, aimed at managing rheumatoid arthritis. The company has a licensing arrangement in place with Factor Bioscience Limited. Established in 2018, this Cambridge, Massachusetts-based entity operated as Eterna Therapeutics Inc. until its rebranding to Ernexa Therapeutics in March 2025.